Renin angiotensin system and ASCVD

Current Opinion in Cardiology

Volumn 15, Issue 3, 2000, Pages 141-150

  Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PERINDOPRIL; QUINAPRIL; RECOMBINANT VASCULOTROPIN; RENIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FIBRINOLYSIS; HUMAN; HUMAN CELL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; LIPOPROTEINS, LDL; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0034076311     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200005000-00004     Document Type: Review

References (43)

1. 1 Tigerstedt R, Bergman PG: Nere Und Kreislauf. Skandinavisches Archiv für Physiologie 1898, 8:223-271.
2. 2 Goldblatt H: Studies on experimental hypertension V. The pathogenesis of experimental hypertension due to renal ischemia. Ann Int Med 1937, 11:69-103.
3. 3 Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Lara GH: Plasma renin activity: a risk for myocardial infarction in hypertensive patients. Am J Hypertens 1997, 10:1-8.
4. 4 Tiret L, Rigat B, Visvikis A, Breda C, Corvol P, Cambien S, et al.: Evidence from combined segregation and linkage analysis, that a variant of the angiotensin-I converting enzyme gene controls plasma ACE levels. Am J Hum Genet 1992, 51:197-205.
5. 5 Akar N, Aras O, Omurlu K, Cin S: Deletion polymorphism at the angiotensin converting enzyme in Turkish patients with coronary artery disease. Scan J Clin Invest 1998, 58:491-496.
6. 6 Gardemann A, Fink M, Sticker J, Nguyen OD, Humme J, Katz : ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. Atherosclerosis 1998, 139:153-159.
7. 7 O'Malley JT, Maslen CL, Illingworth DR: Angiotension-converting enzyme and cardiovascular disease risk. Curr Opin Lipidol 1999, 10:407-415.
8. 8 Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, et al.: Angiotensin-II induces LOX-1, the human endothelial receptor for oxidized low density lipoprotein. Circulation 1999, 100:899-902.
9. 9 Prasad A, Husain S, Quyyumi AA: Effect of enlalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol 1999, 84:1-6.
10. 10 Wilmink HW, Banga JD, Hijmering M, Erkelens WD, Stroes ES, Radelink TJ: Effect of angiotensin converting enzyme inhibition in angiotensin-II type 1 receptor antagonism in postprandial endothelial function. J Am Coll Cardiol 1999, 34:104-105.
11. 11 Kurz S, Hink U, Nickenig G, Borthayre AB, Harrison DG, Munzel T: Evidence for a causal role of the renin angiotensin system in nitrate tolerance. Circulation 1999, 99:381-387.
12. 12 Brown NJ, Giner JG, Stein CM, Vaugh DE: Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999, 33:1431-1435.
13. 13 Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Buffe R: Angiotensin converting enzyme inhibitor ramiprilat interferes with the sequestration of the B-2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999, 99:204-240.
14. 14 Prasad A, Husain S, Quyyumi AA: Abnormal flow mediated epicardial vasomotion in human coronary arteries is improved by angiotensin converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol 1999, 33:796-804.
15. 15 Koh KK, Bui NN, Hathaway L, Csako G, Waclawiw NA, Panza JA, et al.: Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 1999, 83:327-331.
16. 16 Hornig B, Arakawa N, Haussmann D, Drexler H: Differential effect of quinaprilat and enlalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998, 98:2842-2848.
17. 17 Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
18. 18 Keidar S, Kaplan M, Shapira C, Brook JG, Adiram M: Low density lipoprotein isolated from patients with essential hypertension exhibit increased propensity for oxidation and enhanced uptake by microphages: a possible role for angiotensin-II. Atherosclerosis 1994, 107:71-84.
19. 19 Keidar S, Kaplan M, Adiram M: Angiotensin-II modified LDL is taken up by macrophages via the scavenge receptor leading to cellular cholesterol accumulation. ArteriosclerThromb Vasc Biol 1996, 16:97-105.
20. 20 Keidar S: Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998, 63:1-11.
21. 21 Scheidegger KJ, Butler S, Witztum JL: Angiotensin-II increases macrophage mediated modification of low density lipoprotein via a lipoxygenase dependent pathway. J Biol Chem 1997, 272:21609-21615.
22. 22 Keidar S, Attias J, Smith J, Breslow JL, Hayek T: The angiotensin-II receptor antagonist losartan inhibits LDL peroxidation and atherosclerosis in apo-E deficient mice. Biochem Biophys Res Commun 1997, 236:622-625.
23. 23 Bagdade JD, Liu XQ, Buchanan WF, Hafner , Rosenson R: Accelerated cholesterol ester transfer in patients with essential hypertension and the effect of ramipril treatment. Atherosclerosis 1998, 140:167-172.
24. 24 Ridker EM, Rifai N, Pheffer MA, Saks F, Braunwald E: Long term effect of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Current Events (CARE) Investigators. Circulation 1999, 100:230-235.
25. 25 Ridker EM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336(14):973-9.
26. 26 Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kublar W: Angloprotein induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:1623-1629.
27. 27 Liuzzo G, Vaisucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, et al.: J Am Coll Cardiol 1999, 34:1696-1703.
28. 28 Kranzhofer R, Browatzki M, Schmidt J, Kubler W: Angiotensin-II activated the pro-inflammatory transcription factor nuclear factor-kappa-B in human monocytes. Biochem Biophys Res Commun 1999, 257:826-828.
29. 29 Hernandez-Presa
30. 30 Grafe M, Auch-Schweld W, Zakrzewicz A, Regitz-Zagrosek D, Bartsch P, Graf K, et al.: Angiotensin-II induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997, 81:804-811.
31. 31 Brown NJ, Agirbasli M, Vaughan DE: Comparative effect of angiotensin converting enzyme inhibition and angiotensin-II type 1 receptor antagonism on plasma fibrinolytic activity in humans. Hypertension 1999, 34:285-290.
32. 32 Moriyama Y, Ogawa H, Oshima S, Takazoe K, Honda Y, Hirashima O, et al.: Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. Jpn Cire J 1997, 61:308-314.
33. 33 Goodfield NE, Newby DE, Ludam CA, Flapan AD: Effects of acute angiotensin-II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999, 99:2983-2985.
34. 34 Fogari R, Zoppi A, Lazzari P, Preti T, Mugellini A, Corraiadi L, et al.: ACE inhibition but not angiotensin-II antagonism reduced plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998, 32:616-620.
35. 35 Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, Jimenez AM, Gonzales-Fernandez F, Rico LA, et al.: Effect of losartan on human platelet activation. J Hypertens 1999, 17:447-452.
36. 36 Zurbano NJ, Anguera I, Heras M, Roig F, Lozano M, Sanz G, et al.: Captopril administration reduces thrombus formation and service expression of platelet glycoprotein IIb/IIIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999, 19:1791-1795.
37. 37 Soejima H, Ogawa H, Yasue H, Kaikita K, Takazoe K, Nishiyama K, et al.: Angiotensin converting enzyme inhibition reduces monocyte chemoattractant protein-I and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999, 34:983-988.
38. 38 Fabre JE, Rivard A, Magner M, Silver M, Isner JM: Circulation 1999, 99:3043-3049.
39. 39 Hoshida S, Yamashita N, Kawahara K, Kuzuya T, Hori M: Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis of possible mechanisms. Circulation 1999, 99:434-440.
40. 40 Dorge H, Behrends M, Schulz R, Jalowy A, Heusch G: Attenuation of myocardial stunting by the AT-1 receptor antagonist candesartan. Basic Res Cardiol 1999, 94:208-214.
41. 41 Thai HM, Van HT, Gaballa MA, Goldman S, Raya TE: Effects of AT-1 receptor blockade after myocardial enfarct on myocardial fibrosis, stiffness and contractility. Am J Physiol 1999, 276(3 Part 2):H873-H880.
42. 42 Ju H, Zhao S, Jassal DS, Dixon IM: Effect of AT-1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 1997, 35:223-232.
43. 43 Brooksby T, Robinson PJ, Segal R, Klinger G, Pitt B, Cowley AJ: Effect of losartan and captopril on OT dispersion in elderly patients with heart failure. ELITE Study Group. Lancet 1999, 354:395-396.